Hims & Hers Health Inc.（HIMS）股价在盘后交易中大幅下跌6.05%，引发市场关注。这家数字医疗保健公司的股价波动可能与最近减肥药市场的政策变化有关。
根据最新消息，大型保险公司Cigna宣布将在其药房福利管理计划中引入新的条款，为使用热门减肥药Wegovy和Zepbound的患者提供每月200美元的自付费用上限。这一举措可能会影响到Hims & Hers等公司在减肥药市场的竞争格局。
此外，美国食品和药物管理局（FDA）允许销售复方制剂Wegovy和Zepbound的政策将于5月22日结束。这一政策变化可能会直接影响Hims & Hers等公司销售这些产品的能力。投资者可能正在权衡这些因素对公司未来业务的潜在影响，导致股价出现明显下跌。然而，目前尚无官方声明解释股价下跌的具体原因，投资者应密切关注公司后续公告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.